People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Software / Tech, Other Technology, Other Energy, Mining & Resources, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Heartflow, Inc. | — | Biotechnology | Series D+ | $391.8M | $2.7B | 2010 |
| JenaValve Technology Inc | — | Software / Tech | Series D+ | $328.5M | $2.2B | 2017 |
| Adient Medical, Inc. | — | Biotechnology | Series A | $18.2M | $206.8M | 2021 |
| Euphrates Vascular, Inc. | — | Biotechnology | Series A | $9.7M | $322.2M | 2018 |
| Summit Access, LLC | — | Other Technology | Pre-Seed | $2.1M | $11.0M | 2017 |
| Nuscale Power Inc | — | Other Energy | Pre-Seed | $1.5M | $16.1M | 2009 |
| Certrax Risk Compliance Solutions, Inc. | — | Other Technology | Seed | $1.4M | $49.4M | 2016 |
| Aurvista Gold Corp | — | Mining & Resources | Pre-Seed | $1.1M | $4.2M | 2016 |
| Harvest 600, LLC | — | Other | Pre-Seed | $300K | $3.6M | 2021 |
Robert Mitchell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Mitchell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| Casey Tansey | 1 | 14 |
| MICHAEL HOGAN | 1 | 8 |
| Sean Morris | 1 | 7 |
| Dana Mead | 1 | 7 |
| ERIC MOESSINGER | 1 | 6 |
| John Stevens | 1 | 6 |
| Quan Zhou | 1 | 5 |
| Andrew Hack | 1 | 5 |
| Bryan Grulke | 1 | 4 |
| Jan Pensaert | 1 | 3 |
| Kenneth MacLeod | 1 | 3 |
| Rudi Marien | 1 | 3 |
| Brian O'Keefe | 1 | 3 |
| JOSEPH HOOPER | 1 | 3 |
| Casey K. Tansey | 1 | 3 |
| THOMAS HILLMAN | 1 | 3 |
| Maurice Gunderson | 1 | 2 |
| Lee Geist | 1 | 2 |
| Philip M. Young | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.